Figure 7.
Effect of pretreatment with methotrexate on enhanced activity of oral administration of TJ-41 against influenza virus-specific IgG antibody response in sera (A) and of influenza virus-specific IgA antibody response in nasal washes (B) of early aged BALB/c mice. Early aged BALB/c mice, which were secondary immunized with intranasal inoculation of influenza A/PR/8 HA vaccine, were administered orally with methotrexate (20 mg kg−1) twice at Day −3 and Day 25, and the mice were also administered with TJ-41 or TJ-48 (100 mg kg−1 per day) from Day −7 to Day 42. Influenza virus-specific IgG and IgA antibodies were measured for sera and nasal washes collected at Day 42, respectively.